Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was $0.16 for the day, up 98.02% from the previous closing price of $0.08. In other words, the price has increased by $98.02 from its previous closing price. On the day, 784.75 million shares were traded. ADAP stock price reached its highest trading level at $0.179 during the session, while it also had its lowest trading level at $0.0828.
Ratios:
Our analysis of ADAP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.52.
On June 26, 2025, Mizuho Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $0.50. On July 30, 2024, H.C. Wainwright started tracking. The Stock assigning a Buy rating and target price of $4.H.C. Wainwright initiated its Buy rating on July 30, 2024, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 02 ’25 when Wood Gavin sold 96,000 shares for $0.01 per share. The transaction valued at 950 led to the insider holds 0 shares of the business.
Gavin Wood bought 16,000 shares of ADAP for $942 on Sep 02 ’25. On Aug 28 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 207,000 shares for $0.01 each. As a result, the insider received 2,091 and left with 986,352 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 42408252 and an Enterprise Value of 277068512. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 0.65. Its current Enterprise Value per Revenue stands at 4.257 whereas that against EBITDA is -2.019.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.30, which has changed by -0.83935744 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.07, while it has fallen to a 52-week low of $0.04. The 50-Day Moving Average of. The Stock is 30.16%, while the 200-Day Moving Average is calculated to be -53.59%.
Shares Statistics:
ADAP traded an average of 47.81M shares per day over the past three months and 164546650 shares per day over the past ten days. A total of 265.05M shares are outstanding, with a floating share count of 255.41M. Insiders hold about 3.64% of the company’s shares, while institutions hold 27.58% stake in the company. Shares short for ADAP as of 1756425600 were 25148796 with a Short Ratio of 0.53, compared to 1753920000 on 8345689. Therefore, it implies a Short% of Shares Outstanding of 25148796 and a Short% of Float of 11.49.
Earnings Estimates
The current market rating for Adaptimmune Therapeutics Plc ADR (ADAP) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.47 and -$0.47 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $15.4M to a low estimate of $9.03M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $40.9MFor the next quarter, 4 analysts are estimating revenue of $15.23M. There is a high estimate of $20.1M for the next quarter, whereas the lowest estimate is $9.7M.
A total of 1 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $40.4M, while the lowest revenue estimate was $40.4M, resulting in an average revenue estimate of $40.4M. In the same quarter a year ago, actual revenue was $178.03MBased on 4 analysts’ estimates, the company’s revenue will be $64.09M in the next fiscal year. The high estimate is $85M and the low estimate is $41.4M.
